By UnHideA Senior EditorsOriginal source:Morgan StanleyFirst published on UnHideA:Original source date:
Key takeaway
Zoryve demand growth prompted Morgan Stanley to raise its full-year sales estimate, but near-term growth depends on prescription volume and ongoing investment; the firm expects more pronounced operating leverage only by year-end 2027 or in 2028.
Where did third-quarter growth come from?
Zoryve third-quarter net product revenue was about $144 million, up 11% sequentially and 45% year over year; both Morgan Stanley and the market consensus expected about $143 million. The result was broadly in line with expectations, rather than a significant beat.
Demand spans different indications and formulations. Quarterly prescriptions exceeded 300 thousand, up 11% sequentially and 34% year over year; the company said prescription demand continued to grow despite seasonal headwinds.
Revenue growth was driven mainly by volume: the third-quarter GTN discount rate was just above 50%, and management expects it to remain stable, leaving limited scope for sales growth from pricing.
What level does fourth-quarter revenue need to reach after the full-year guidance increase?
Management raised its 2026 net product revenue guidance from $525 million–$540 million to $535 million–$545 million. Under this guidance, fourth-quarter revenue needs to reach about $156 million–$166 million, an increase of about 8%–15% from the third quarter.
This growth trajectory still centers on volume: management expects seasonality and commercial investment to support fourth-quarter demand, while GTN is expected to remain broadly stable and pricing to make a limited contribution. Morgan Stanley raised its 2026 revenue forecast to about $542 million, near the high end of guidance, and maintained its $38 price target and Overweight rating.
How will commercial investment support growth in 2027?
The company added 30 dermatology sales representatives, expanding the team to 160; the new representatives began field work in early May. Management attributed part of the demand recovery in September to the team expansion and expects its contribution to increase further in the fourth quarter and in 2027.
Prescription reminders and greater emphasis on refills when prescribing also improved patient adherence. A primary care/pediatrics pilot involving about 20 people launched in late August, with early signs of new and reactivated prescriptions; management expects its impact on demand to become clearer in 2027, and new direct-to-consumer advertising is also expected to contribute more noticeably in early 2027.
Will faster sales growth immediately translate into operating leverage?
Third-quarter operating cash flow was about $19 million, and cash and marketable securities at quarter-end were about $260 million, providing a funding base for continued investment. However, selling and marketing expenses were about $100 million, including advertising and sales-team costs, and management expects spending in the fourth quarter to remain near current levels.
The company continues to prioritize reinvestment. Morgan Stanley expects more pronounced operating leverage only by year-end 2027 or in 2028, so sales growth and margin improvement will not occur in tandem.
Which pipeline milestones could expand future growth opportunities?
The company has initiated a Phase III trial in moderate-to-severe atopic dermatitis. Phase II vitiligo data and a decision on whether to advance the program are expected in the fourth quarter of 2026; Phase II hidradenitis suppurativa data and an advancement decision are expected by the end of the first quarter of 2027.
The regulatory review date for the infant atopic dermatitis treatment is 23 February 2027. These milestones relate respectively to a trial, advancement decisions, and regulatory review, and could provide future catalysts for expanding Zoryve's indications.